DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HUMAN ENDOMETRIAL SPECIFIC STEROID-BINDING FACTOR I, II AAND III

the specification of which [] is attached hereto or [X] was filed on March 21, 1997 as Application Serial No. 08/821,451.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s):

			Fliority Claim	<u> </u>
(Number)	(Country)	(Day/Month/Year Filed)		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

60/014724	March 21, 1996	pending
(Provisional Application Serial No.)	(Filing Date)	(Status - patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: John N. Bain (Reg. No. 18,651); John G. Gilfillan, III (Reg. No. 22,746); Elliot M. Olstein (Reg. No. 24,025); Raymond J. Lillie (Reg. No. 31,778); Charles J. Herron (Reg. No. 28,019); William Squire (Reg. No. 25,378); and J.G. Mullins (Reg. No. 33,073). Address correspondence and telephone calls to Charles J. Herron c/o Carella, Byrne, Bain, Gilfillan; Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 - (201) 994-1700.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Jian Ni		Date: (2/9/97)
Inventor's signature: Residence: 5502 Manorfield Road, Rockville, MD 20853 Post Office Address: same	Citizenship: USA	Date:
Full name of second joint inventor: Guo-Liang Yu Inventor's signature: Residence: 13524 Straw Bale Lane, Darnestown, MD 20878 Post Office Address: same	Citizenship: China	Date: 1/22/98
Full name of third joint inventor: Reiner Gentz Inventor's signature: Residence: 13404 Fairland Park Drive, Silver Spring, MD 20904 Post Office Address: same	Citizenship: Ge	Date: [-(2-98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ni et al.

Application No.: 09/985,911-Conf. #4521 Group Art Unit: 1652

Filed: November 6, 2001 Examiner: C.L. Patterson, Jr

For: Human Endometrial Specific Steroid-Binding Atty. Docket No.: PF257D3

Factor I, II, and III

STATEMENT UNDER 37 C.F.R. § 3.73, REVOCATION OF PRIOR POWERS OF ATTORNEY OR AUTHORIZATIONS OF AGENT; AND POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Statement Under 37 C.F.R. § 3.73

Human Genome Sciences, Inc. ("HGS"), organized and existing under the laws of the State of Delaware, having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850, states that it is the assignee of record of the entire right, title and interest for the above-identified application by virtue of an assignment from the inventors, recorded in the U.S. Patent and Trademark Office on December 15, 1998, at Reel 9640, Frame 0619. This assignment was directed to the great-grandparent of the present application, U.S. Application No. 08/821,451, filed March 21, 1997 (now U.S. Patent No. 6,066,724, issued May 23, 2000), and all continuation and divisional applications thereof.

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of HGS. The undersigned has reviewed all the documents in the chain of title of the above-captioned application, and, to the best of the undersigned's knowledge and belief, HGS has title in the application as described above.

Application No.: 09/985,911 Docket No.: PF257D3

Revocation of Prior Powers of Attorney or Authorizations of Agent

HGS hereby revokes all previous powers of attorney or authorizations of agent given in the above-captioned application.

Power of Attorney or Authorization of Agent

HGS hereby appoints the Practitioners at Customer Number 22195 as its attorneys or agents with full power of substitution, association, and revocation to prosecute the above-captioned application, including any continuations or divisionals thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith.

On behalf of Human Genome Sciences, Inc.:

For: Human Genome Sciences, Inc.
Signature:
Name: James H. Davis, Ph.D.
Title: Executive Vice President, General Counsel, and Secretary
Date: April 1, 2004